Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis, according to the company’s website (see here: http://pvct.com/index.html). SNNLive spoke with Peter R. Culpepper, CFO and COO of Provectus Biopharmaceuticals, Inc. at the Growth Capital Expo 2015 in Las Vegas, NV.
Mr. Culpepper begins the interview with an overview of PVCT. He continues to discuss the various clinical programs Provectus has done for PV-10 and PH-10, as well as, when the company expects the drugs to be available in the market. Mr. Culpepper then explains how the science works, as well as the history of the company and it’s compounds.
Mr. Culpepper concludes the interview by discussing his insights on 2015 and 2016. For more information about Provectus Biopharmaceuticals, Inc., go to www.PVCT.com
Since speaking with Mr. Culpepper, the company has made the following announcements:
© 2017 Stock News Now
Supported by Superior Web Solutions